SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Takeda says zasocitinib showed superior efficacy in Phase 3 psoriasis study

Takeda said new Phase 3 LATITUDE Atlas data showed zasocitinib was statistically superior to deucravacitinib across primary and key secondary endpoints. The company also cited durable skin clearance and no new safety signals.

4502.T

Related stories